trending Market Intelligence /marketintelligence/en/news-insights/trending/esxZzTx8qdQm08CzR0MGdQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Histogenics terminates CEO, COO, reduces staff under cost-saving restructuring

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Histogenics terminates CEO, COO, reduces staff under cost-saving restructuring

Histogenics Corp. is terminating the positions of CEO Adam Gridley and COO Stephen Kennedy as part of a restructuring plan to reduce costs and eliminate all but one of the company's employees.

Histogenics expects to record a one-time charge of about $2.2 million in severance and related expenses. The company intends to substantially complete the restructuring by the end of the first quarter.

Histogenics' evaluation of strategic alternatives is expected to be handled by Gridley and Kennedy, who will continue to consult the company, along with up to four additional employees who the company intends to engage as consultants upon their separation from service.

Gridley will retain his statutory titles as president, treasurer and secretary of the Waltham, Mass.-based clinical-stage company and will remain a director of Histogenics but will not receive compensation for the position.